PPD has entered into an agreement to acquire Excel PharmaStudies.

Following the transaction, Excel PharmaStudies will become a wholly-owned subsidiary of PPD.

The transaction is expected to close in the fourth quarter of 2009.

Deal Type    Acquisition
Sub-Category Majority Acquisition
Deal Status  Completed: 2009-11-06

Deal Participants

Target (Company)   Excel PharmaStudies, Inc.
Acquirer (Company) Pharmaceutical Product Development, Inc.

Deal Rationale

The transaction will provide PPD an additional capacity and expertise in this growing market and will increase its client base in Asia Pacific. The acquisition will strengthen PPD's ability to offer Phase II-IV clinical, data management, biostatistics, regulatory and quality assurance services. By combining Excel's drug development expertise with its global central laboratory operations in Beijing and Singapore will position PPD to deliver a broad set of services to biopharmaceutical companies in China, Japan and throughout the Asia Pacific region.

PPD has entered into an agreement to acquire Excel PharmaStudies.

Following the transaction, Excel PharmaStudies will become a wholly-owned subsidiary of PPD.

The transaction is expected to close in the fourth quarter of 2009.

Deal Type    Acquisition
Sub-Category 100% Acquisition
Deal Status  Completed: 2009-11-06

Deal Participants

Target (Company)   Excel PharmaStudies, Inc.
Acquirer (Company) Pharmaceutical Product Development, Inc.

Deal Rationale

The transaction will provide PPD an additional capacity and expertise in this growing market and will increase its client base in Asia Pacific. The acquisition will strengthen PPD's ability to offer Phase II-IV clinical, data management, biostatistics, regulatory and quality assurance services. By combining Excel's drug development expertise with its global central laboratory operations in Beijing and Singapore will position PPD to deliver a broad set of services to biopharmaceutical companies in China, Japan and throughout the Asia Pacific region.

The transaction is expected to close in the fourth quarter of 2009.

Deal Type    Acquisition
Sub-Category Majority Acquisition
Deal Status  Announced: 2009-10-27

Deal Participants

Target (Company)   Excel PharmaStudies, Inc.
Acquirer (Company) Pharmaceutical Product Development, Inc.

Deal Rationale

The transaction will provide PPD an additional capacity and expertise in this growing market and will increase its client base in Asia Pacific. The acquisition will strengthen PPD's ability to offer Phase II-IV clinical, data management, biostatistics, regulatory and quality assurance services. By combining Excel's drug development expertise with its global central laboratory operations in Beijing and Singapore will position PPD to deliver a broad set of services to biopharmaceutical companies in China, Japan and throughout the Asia Pacific region.